Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model.
about
Renal and neurological side effects of colistin in critically ill patientsColistin in Pig Production: Chemistry, Mechanism of Antibacterial Action, Microbial Resistance Emergence, and One Health PerspectivesFull virulence of Pseudomonas aeruginosa requires OprFThe periplasmic protein TolB as a potential drug target in Pseudomonas aeruginosaMathematical modeling of bacterial kinetics to predict the impact of antibiotic colonic exposure and treatment duration on the amount of resistant enterobacteria excretedDistinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic ModelingElucidation of the Mode of Action of a New Antibacterial Compound Active against Staphylococcus aureus and Pseudomonas aeruginosaDefining the Active Fraction of Daptomycin against Methicillin-Resistant Staphylococcus aureus (MRSA) Using a Pharmacokinetic and Pharmacodynamic ApproachAntimicrobial Activity and Resistance: Influencing Factors.Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model.Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.'Old' antibiotics for emerging multidrug-resistant bacteriaPredicting in vitro antibacterial efficacy across experimental designs with a semimechanistic pharmacokinetic-pharmacodynamic model.Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumanniiDosing of colistin-back to basic PK/PD.Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosingSynergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic modelMulti-scale model of drug induced adaptive resistance of Gram-negative bacteria to polymyxin B.Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?Optimizing Polymyxin Combinations Against Resistant Gram-Negative BacteriaQuantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing designOptimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosaParadoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumanniiOptimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease.Effect of colistin on phospholipid-based activated partial thromboplastin time clotting assay results in patients receiving concomitant heparin therapy.Polymyxin B versus colistin: an update.Pharmacokinetics and pharmacodynamics in antibiotic dose optimization.Pharmacodynamics of dose-escalated 'front-loading' polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli.A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants.High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii.Clinical Pharmacokinetics and Pharmacodynamics of Colistin.Mutant prevention concentration of colistin alone and in combination with rifampicin for multidrug-resistant Acinetobacter baumannii.A pharmacokinetic-pharmacodynamic model characterizing the emergence of resistant Escherichia coli subpopulations during ertapenem exposure.Individual and Combined Effects of Engineered Peptides and Antibiotics on Pseudomonas aeruginosa Biofilms.
P2860
Q27499294-AC5B56E1-3156-4C72-A089-738CEE4E754EQ28076261-499AE776-14AF-4DE3-8DF8-D2764F1D44EFQ28492965-66F8BB18-0085-48FE-898B-4C656E9E1C87Q28541613-E3C85385-D255-4A72-8031-5BAF92543A03Q28542920-2F0784BC-E9CA-42A5-9317-4A6444310BC9Q28550711-54CE38C9-2791-44AB-87BE-6BF80A1A4365Q28551971-2C4F71B4-0E4E-4EB8-A7B2-9A51C6016BA9Q28601378-B9995CEB-3308-4C01-B67B-AEF65987D87AQ33790192-DAF9098D-85EE-43E6-8D3E-18512EF28CC1Q34108660-1F80881D-B9A5-45EF-A9FD-2C7541EECF89Q34327857-B644512F-06E8-4971-B9FB-C05C5F707FCBQ34552966-E0D3BA7A-DB9C-48C8-9868-6E69B3D4C576Q34565772-E291AB0F-0F39-4965-8A37-DA574156A501Q34737629-C9F9CBFF-4E87-4CD6-87D5-E791AAA487ACQ35168882-D22CBE27-FAD4-49B3-9991-98B9B69CD52AQ35168931-49792C34-07C2-413C-8341-CE62AAFF88A7Q35242165-0AFCBD07-B9DC-449E-8288-0B8B022965E2Q35364351-6913D4D9-18FB-4B43-83A5-4924ADAE83E2Q35432770-C2778ED2-493F-4987-B338-CE0B0DBB4170Q35541277-72981DD6-675D-4F44-B8FF-B13D1F5F9ECAQ35598403-8869DBA2-2496-42AC-9BB3-7D46205DEED1Q36276852-A8C65027-3E93-4262-8FCD-508AC650F4B2Q36319990-040345A1-70BE-4F1C-902D-11C432ED6F96Q36335694-03CAB2DF-7817-4A0F-A8F5-5F15576BDE44Q36363261-2383A166-508E-4A4C-A422-F6CA51858EDDQ36785827-B77E5570-2C22-49A2-8C87-8E43B78C9669Q36887819-99154478-365B-4C5E-8B9C-B9D249E0F939Q37023206-C90F27A4-DE11-4150-A332-F9B3FE086945Q37538623-EB90BF93-DF77-4E91-9F65-AA2FE59DE218Q37643631-B84042EA-3A7B-45E6-B0AA-DEDE042426CFQ37848401-CA86D413-7111-414D-89C4-CBFE1BC42303Q38613051-686DB71E-EC94-47FA-ABB3-4789E6F2AC9DQ38664871-AE67115E-802F-492E-BFB6-7006BF78B536Q38785797-192FACCB-9294-42D5-A986-BCC7C5D396E9Q38966188-834F093B-4D38-4C2C-8612-355C345DEBE3Q39170967-D21A9D7B-B538-457D-A693-0C6DFDC50827Q39333751-3DD603C2-ABCB-449A-85D1-2E5BF5B65D7FQ39503267-CC05D6EC-72B7-4942-B10B-C36BC797A030Q39665401-308D2EC7-DEA8-464E-858B-66E888E2F765Q40149019-18B7DFCD-9923-4B7C-843A-CEE3E050F4D9
P2860
Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Attenuation of colistin bacter ...... ulation pharmacodynamic model.
@ast
Attenuation of colistin bacter ...... ulation pharmacodynamic model.
@en
type
label
Attenuation of colistin bacter ...... ulation pharmacodynamic model.
@ast
Attenuation of colistin bacter ...... ulation pharmacodynamic model.
@en
prefLabel
Attenuation of colistin bacter ...... ulation pharmacodynamic model.
@ast
Attenuation of colistin bacter ...... ulation pharmacodynamic model.
@en
P2093
P2860
P356
P1476
Attenuation of colistin bacter ...... ulation pharmacodynamic model.
@en
P2093
Alan Forrest
Brian T Tsuji
Jenny C Yang
Liliana Yohonn
Rebecca E D'Hondt
Silvia V Brown
William J Jusko
P2860
P304
P356
10.1128/AAC.00881-09
P407
P577
2010-03-08T00:00:00Z